Information:
Error:
ID
22340
Description
Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00314873
Link
https://clinicaltrials.gov/show/NCT00314873
Keywords
Versions (1)
- 5/30/17 5/30/17 -
Uploaded on
May 30, 2017
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Thymic Carcinoma NCT00314873
Eligibility Thymic Carcinoma NCT00314873
- StudyEvent: Eligibility
Similar models
Eligibility Thymic Carcinoma NCT00314873
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
c-kit and pdgfr positive thymic carcinoma
Item
histological or cytological proof of advanced c-kit positive or pdgfr positive thymic carcinoma. for protocol purposes, advanced disease is defined as disease
boolean
C0205969 (UMLS CUI [1,1])
C0072470 (UMLS CUI [1,2])
C0071253 (UMLS CUI [1,3])
C0072470 (UMLS CUI [1,2])
C0071253 (UMLS CUI [1,3])
measuable thymic carcinoma lesion
Item
patient must have at least one documented measurable lesion obtained by imaging within 28 days prior to being registered for protocol therapy.
boolean
C0205969 (UMLS CUI [1,1])
C1513041 (UMLS CUI [1,2])
C1513041 (UMLS CUI [1,2])
imatinib
Item
no prior imatinib therapy.
boolean
C0935989 (UMLS CUI [1])
age
Item
age > 18 years at the time of consent
boolean
C0001779 (UMLS CUI [1])
ecog
Item
ecog performance status of 0 or 1
boolean
C1520224 (UMLS CUI [1])
anc, platelet count, total bilirubin, serum creatinine, alt, ast
Item
anc ≥ 1500/mm3,platelet count ≥ 100,000/mm,total bilirubin < 1.5uln,3.10 serum creatinine ≤ 1.7 mg/dl,alt and ast ≤ 3 x uln
boolean
C0948762 (UMLS CUI [1])
C0005821 (UMLS CUI [2])
C0201913 (UMLS CUI [3])
C0201976 (UMLS CUI [4])
C0201836 (UMLS CUI [5])
C0201899 (UMLS CUI [6])
C0005821 (UMLS CUI [2])
C0201913 (UMLS CUI [3])
C0201976 (UMLS CUI [4])
C0201836 (UMLS CUI [5])
C0201899 (UMLS CUI [6])
infections
Item
clinically significant infections as judged by the treating investigator
boolean
C0009450 (UMLS CUI [1])
comorbidity
Item
clinically significant concurrent illnesses
boolean
C0009488 (UMLS CUI [1])
females of childbearing potential birth control, breastfeeding
Item
females of childbearing potential not using birth control or breastfeeding
boolean
C1960468 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0006147 (UMLS CUI [2])
C0700589 (UMLS CUI [1,2])
C0006147 (UMLS CUI [2])
bone marrow radiation therapy
Item
prior radiation therapy > 25% of the bone marrow
boolean
C1522449 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0005953 (UMLS CUI [1,2])
symptomatic brain metastasis
Item
symptomatic brain metastasis
boolean
C0220650 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C0231220 (UMLS CUI [1,2])
cardiac problems
Item
history of grade iii/iv cardiac problems
boolean
C0262402 (UMLS CUI [1])
major surgery
Item
history of major surgery within 14 days prior to being registered
boolean
C0679637 (UMLS CUI [1])
investigational agent
Item
treatment with any investigational agent within 30 days prior to being registered for protocol therapy.
boolean
C0013230 (UMLS CUI [1])